Lupus Tumidus with Severe or Disseminated CLE — What to Do After Methotrexate Has Not Worked

This protocol applies to patients with lupus tumidus presenting with severe or disseminated cutaneous lupus erythematosus skin lesions whose disease activity did not improve sufficiently on a prior course of methotrexate.

Clinical Scenario

Severe or disseminated CLE skin lesions require sustained systemic treatment, including in patients at risk of scarring. Antimalarial drugs are recommended as the long-term foundation of therapy in all such patients.

Prior Treatment — Failure Condition

This protocol is triggered by inadequate response to methotrexate (used in combination with antimalarial drugs). The escalation criterion is failure to achieve meaningful improvement in cutaneous lupus erythematosus disease activity after 3–6 months on that regimen.

Next Step — Partial Overview

The protocol introduces a retinoid-class agent or a selected alternative for refractory disease, preferably in combination with antimalarial drugs. Response is evaluated within the first weeks of treatment; full efficacy assessment is recommended at 3–6 months. The complete agent selection, sequencing, and monitoring guidance is in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14491

Antimalarial drugs are recommended as first-line treatments, also for long-term therapy, in all CLE patients with severe and disseminated skin lesions; in particular for patients with a risk of scarring.

For severe or disseminated CLE lesions, systemic glucocorticoids are recommended as first-line treatment in addition to antimalarial drugs, for a limited period of time.

Retinoids are sugested as a second-line systemic treatment for all other forms of CLE.

Dapsone is suggested as second-line therapy for refractory CLE, preferably in combination with antimalarial drugs.

Response usually occurs rapidly within the first 2-6 weeks after treatment initiation.

It is recommended to evaluate the efficacy of systemic treatment for CLE after a minimum of three months and a maximum of six months (except for glucocorticoids).

View source ↗